Category: Technology

Categories
Business Technology

Iron Mountain data centers among the first to track renewable energy by the hour

Hourly tracking of renewable energy load matching illustrates a future view of how companies will transition to a carbon-free energy supply

BOSTON — (BUSINESS WIRE) — $IRM #CarbonFree–Iron Mountain Incorporated (NYSE:IRM), the storage and information management services company, today announced that it has taken a significant step forward in the development of enhanced solutions for purchasing renewable energy, through readily available retail channels, by entering into an agreement with RPD Energy and Direct Energy to track the hourly renewable energy load of Iron Mountain data centers.

The innovative structure will source 100% renewable energy aimed at matching the hourly usage of all Iron Mountain facilities in Pennsylvania and New Jersey (over 60 buildings), including two data centers. Conventional renewable power solutions seek to only match a buyer’s load on an annual or monthly basis without ensuring renewable power is available when clients are using electricity. Tracking hourly usage from the generator and comparing it to Iron Mountain’s hourly usage demonstrates a future view of how firms can transition to truly carbon free energy supply.

“Iron Mountain is seeking to move beyond the conventional approach of matching renewable power on an annual basis, to matching renewable power generation with its hourly energy use. This is ultimately the path needed to decarbonize energy use,” stated Chris Pennington, Global Energy Manager at Iron Mountain Data Centers. “We are proud to push the marketplace and be at the forefront of embracing and adopting this unique approach and believe that RPD and Direct Energy have assembled a highly repeatable product that will become a readily available retail product.”

“It is so gratifying to witness the power of collaboration and we hope transactions like these can demonstrate that the market is capable of greater flexibility to meet increasingly aggressive demands for truly 24/7 renewable power,” said Eric Alam, CEO of RPD Energy. “RPD Energy’s role was to identify the right committed generator and retail supplier to ensure that Iron Mountain could achieve a truly unique outcome. Working with Axpo U.S. to design a wholesale transaction that worked for EDP Renewables North America, and with the team at Direct to create the retail product that fit Iron Mountain’s requirements required the kind of patience, resolve, and cooperation across all parties that results in these breakthrough transactions.”

RPD Energy in conjunction with Direct Energy, will provide Iron Mountain a monthly report to document the match of average hourly generation and Iron Mountain’s actual hourly offtake from the grid. To maintain the integrity of the renewable impact of the transaction, traceability and environmental claims are ensured by renewable energy credits provided via EDP Renewables North America and sourced from the same renewable developer.

About Iron Mountain

Iron Mountain Incorporated (NYSE: IRM), founded in 1951, is the global leader for storage and information management services. Trusted by more than 225,000 organizations around the world, and with a real estate network of nearly 93 million square feet across approximately 1,450 facilities in 56 countries, Iron Mountain stores and protects billions of valued assets, including critical business information, highly sensitive data, and cultural and historical artifacts. Providing solutions that include secure records storage, information management, digital transformation, secure destruction, as well as data centers, cloud services and art storage and logistics, Iron Mountain helps customers lower cost and risk, comply with regulations, recover from disaster, and enable a more digital way of working. Visit www.ironmountain.com for more information.

About RPD Energy

RPD Energy architects green energy solutions for corporate America. RPD offers directly sourced, variable term (2-8 years), right-sized contracts for green energy and RECs from utility-scale wind and solar facilities without the complexity of traditional PPA/VPPAs. Fortune 500 energy buyers have chosen RPD Energy work with their suppliers to provide green energy contracts for their data centers, production facilities and corporate headquarters in several regions across the US. RPD is headquartered in Houston, Texas. www.rpdenergy.com.

Contacts

Iron Mountain

Global Communications:
media@ironmountain.com

Investor Relations:
Greer Aviv

Senior Vice President, Investor Relations

617.535.2887

Greer.Aviv@ironmountain.com

Categories
Business Technology

iQor selects NICE Workforce Management cloud solutions as its global platform to take customer experience to the next level

NICE WFM cloud-based suite helps iQor augment employee scheduling flexibility and improve engagement

HOBOKEN, N.J. — (BUSINESS WIRE) — NICE (Nasdaq: NICE) today announced that iQor has selected the NICE Workforce Management (WFM) cloud-based suite to help teams augment customer experience across its global service locations. iQor, a managed services provider of customer engagement and technology-enabled BPO solutions, is leveraging NICE’s AI and machine learning-based scheduling solution to further engage employees and boost customer satisfaction.

“iQor is dedicated to putting our employees at the forefront,” said Loren Dennis, Senior Vice President Workforce Management, iQor. “NICE helps streamline our workforce management activities so we can plan intelligently and adapt quickly to changes as the market, our customers and employees require them. We are also focused on helping employees feel empowered and experience a better work-life balance.”

iQor is taking its workforce management to the next level by leveraging several key capabilities in NICE WFM. These include AI-enabled forecasting, machine learning-based simulation for scheduling and real-time monitoring of adherence, automated intraday reforecasting and schedule re-simulation. The BPO company is also tapping into NICE’s Employee Engagement Manager (EEM) solution to extend the reach of NICE WFM-based scheduling to agents regardless of their physical location.

“NICE’s accurate, reliable forecasting and staffing solution will enable us to help clients effectively address their workforce management needs,” said Prabhjot Singh, Senior Vice President Technology Innovation, iQor. “We are excited to leverage NICE’s WFM and EEM capabilities to drive further improvements in productivity, employee engagement and customer satisfaction.”

NICE will benefit iQor’s clients by ensuring the right balance of staffing in its operations. It will also further enhance iQor’s ability to rapidly respond to unexpected fluctuations in call volume and accurately plan for seasonality, campaigns and product launches.

“As an organization that understands the power of experiences, we are excited to collaborate with iQor to deliver the benefits of industry-leading workforce management to their employees and customers,” commented Barry Cooper, NICE Workforce & Customer Experience Group President. “In these challenging times, customer service becomes even more critical for business success and so we are pleased to partner with iQor to deliver optimized staffing while consistently increasing the engagement of their employees.”

About NICE

NICE (Nasdaq: NICE) is the world’s leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. NICE helps organizations of all sizes deliver better customer service, ensure compliance, combat fraud and safeguard citizens. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, are using NICE solutions. www.nice.com.

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Cooper, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners; cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

Corporate Media
Christopher Irwin-Dudek, 201-561-4442, chris.irwin-dudek@nice.com

Investors
Marty Cohen, +1-551-256-5354, ir@nice.com, ET

Categories
Business Technology

NICE Robotic Process Automation receives 2020 TMC Labs Innovation Award

NEVA impresses judges with its innovative functionality and ability to drive fast ROI

HOBOKEN, N.J. — (BUSINESS WIRE) — #NICE—NICE (Nasdaq: NICE) today announced that NEVA, its attended automation solution, has won the 2020 TMC Labs Innovation Award from CUSTOMER Magazine. Part of the NICE Robotic Process Automation (RPA) offering, NEVA received the accolade for its impressive functionality and ability to deliver fast ROI, among others.

NICE Employee Virtual Attendant or NEVA is the first employee-focused virtual attendant to hit the global market with the most comprehensive real-time integration and intelligence capabilities. With a proven track record of effectively supporting organizations’ operational and customer service needs, NEVA enables employees, both in the office and at home, to respond instantly and intuitively to customer queries while ensuring full compliance and processing accuracy. NICE was named a Leader by Everest Group and NEVA emerged as a top attended RPA offering in its RPA PEAK Matrix 2021 assessment. NEVA was also ranked as a Market Leader in Intelligent Attended RPA by Zinnov in their 2020 RPA leadership report.

Amardeep Modi, Practice Director at Everest Group, said, “NICE’s attended automation offering, NEVA, is a key contributor to NICE’s leading position in the RPA space and demonstrates the company’s focus on innovation. Clients have attested to NEVA as one of the company’s key strengths and appreciated its functionalities such as customizable callouts that help provide guidance to agents.”

“Congratulations to NICE for earning a 2020 TMC Labs Innovation Award. NEVA (NICE Employee Virtual Attendant) impressed us with its functionality, assistance in ensuring compliance, ability to reduce mundane contact center tasks, and capacity to help customers have their needs taken care of more quickly,” said Rich Tehrani, CEO, TMC. “The solution’s best feature may be its ROI, as well-designed RPA solutions pay for themselves quickly.”

“The past year has demonstrated just how important innovative technology such as NEVA is in preparing businesses to adjust to new and dynamic situations in an agile way”, Barry Cooper, President, NICE Enterprise Group said. “We believe industry recognition from organizations such as TMC serves to validate the strategy and success and are proud to be the recipient.”

About NICE

NICE (Nasdaq: NICE) is the world’s leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. NICE helps organizations of all sizes deliver better customer service, ensure compliance, combat fraud and safeguard citizens. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, are using NICE solutions. www.nice.com.

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Cooper, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

Corporate Media
Christopher Irwin-Dudek, +1 201 561 4442, ET, chris.irwin-dudek@nice.com

Investors
Marty Cohen, +1 551 256 5354, ET, ir@nice.com

Categories
Science Technology

Investigational combination of Aliqopa® (copanlisib) and rituximab significantly increases progression-free survival in patients with relapsed indolent non-Hodgkin’s Lymphoma

  • In the Phase III trial CHRONOS-3 of 458 patients with indolent non-Hodgkin’s Lymphoma (iNHL), the investigational combination of Aliqopa and rituximab was statistically significant in delaying disease progression or death (HR=0.52, 95% CI 0.39, 0.69) compared to rituximab and placebo, with a median progression-free survival (PFS) of 21.5 months (95% CI 17.8, 33.0) versus 13.8 months (95% CI 10.2, 17.5)1
  • The CHRONOS-3 trial included several prespecified iNHL subgroups including follicular lymphoma (FL; n=275), marginal zone lymphoma (MZL; n=95), small lymphocytic lymphoma (SLL; n=50), and lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM; n=38)1
  • Bayer is discussing the data from CHRONOS-3 with health authorities worldwide

Abstract: CT001

WHIPPANY, N.J. — (BUSINESS WIRE) — Results from the randomized, double-blind, placebo-controlled Phase III trial CHRONOS-3 show a significant improvement in progression-free survival (PFS) with the investigational combination of Aliqopa® (copanlisib) and rituximab given intravenously in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to the combination of rituximab and placebo. After a median follow-up of 19.2 months, patients treated with this combination had a median PFS of 21.5 months (95% CI 17.9, 33.0) versus 13.8 months in patients treated with rituximab and placebo (95% CI 10.2, 17.5), (HR=0.52, p=0.000002). No new safety signals were identified for Aliqopa in the combination arm of the study.1 The data will be presented in a Clinical Trials Plenary Session on April 10 at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 and simultaneously published in The Lancet Oncology.

CHRONOS-3 is a Phase III randomized, double-blind, placebo-controlled trial with the objective to evaluate whether Aliqopa in combination with rituximab is superior to placebo plus rituximab in extending PFS in patients with relapsed iNHL following at least one prior rituximab-containing therapy. Patients who had a progression-free and treatment-free interval of at least 12 months after completion of the last rituximab-containing regimen or patients unwilling/unfit or for who chemotherapy was contraindicated by reason of age, co-morbidities and/or residual toxicity were included.2

In 2017, Aliqopa was approved for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies based on the results of a single-arm, multicenter, Phase II clinical trial (CHRONOS-1).3 Accelerated approval was granted for this indication based on overall response rate (ORR). Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.

“In clinical practice, we have seen an overall improvement in the prognosis of iNHL patients, yet relapsed disease is still a prominent treatment challenge,” said Matthew J. Matasar, M.D., Medical Oncologist, Regional Care Network Medical Site Director, Memorial Sloan Kettering Cancer Center (MSK) Bergen. “The results reported with the combination of copanlisib and rituximab suggest a potential advancement for patients with these diverse types of cancers.”

“Bayer is committed to putting patients’ needs first and delivering innovative treatment options that address areas of high unmet need, and clinical research is the first step in that process,” said Scott Z. Fields, M.D., Senior Vice President and Head of Oncology Development at Bayer. “These data highlight the potential of Aliqopa and rituximab as a new strategy for treating these patients and we look forward to advancing regulatory discussions.”

Bayer is in discussions with health authorities worldwide regarding the data from CHRONOS-3.

Additional CHRONOS-3 Data Being Presented at AACR

In addition to the primary endpoint of PFS, data on the secondary endpoints of ORR and complete response rate (CRR) will also be presented. Best ORR for the combination of Aliqopa and rituximab was 80.8% (95% CI 76, 85) versus 47.7% (95% CI 40, 56) for rituximab and placebo (p<0.0001), with 33.9% and 14.6% of patients achieving CR, respectively. Of the relapsed iNHL patients included in the trial, 60% had FL, 20.7% marginal zone lymphoma (MZL), 10.9% small lymphocytic lymphoma (SLL) and 8.3% lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM). Analysis of the subtypes will be presented at AACR and published in The Lancet Oncology.1

All-grade treatment-emergent adverse events (TEAEs) observed with the Aliqopa and rituximab combination that occurred in more than 20% of the patients included hyperglycemia (69.4%), hypertension (49.2%), diarrhea (33.6%), neutropenia (20.8%), nausea (22.5%) and pyrexia (20.5%). Discontinuation due to all-grade TEAEs in CHRONOS-3 for Aliqopa and rituximab was 32% versus 8% for rituximab and placebo.1

Aliqopa is an intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant activity against alpha and delta isoforms the PI3K-alpha and PI3K-delta isoforms expressed in malignant B cells.4 Aliqopa is approved in the U.S. under the accelerated approval pathway for the treatment of adult patients with relapsed FL who have received at least two prior systemic therapies. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Accelerated approval was granted for this indication based on an ORR of 59% (n=61/104; 95% CI 49, 68), including 14% (15/104) of CRs from the open-label, single-arm multicenter, Phase II clinical trial (CHRONOS-1), in a total of 142 subjects, which included 104 subjects with follicular B-cell non-Hodgkin’s Lymphoma who had relapsed disease following at least two prior treatments. In the updated two-year follow-up analysis conducted on data until 16 weeks after the last patients eligible for full analysis started treatment, Aliqopa ORR was 59% (n=61; 95% CI 49, 68), including 20% CR (n=21).5 Tumor response was assessed according to the International Working Group response criteria for malignant lymphoma. Efficacy based on ORR was assessed by an Independent Review Committee.

Disclosure: This study was sponsored by Bayer AG. Dr. Matasar has received honoraria from Bayer AG and subsidiaries of Bayer AG for advising and related activities. Bayer AG also provides research funding for Dr. Matasar through Memorial Sloan Kettering Cancer Center (MSK). In addition, Dr. Matasar has received honoraria from Roche/Genentech for advising and related activities, and the company also provides research funding for him through MSK.

About Aliqopa® (copanlisib) Injection3

Aliqopa (copanlisib) is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. Aliqopa has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines. Aliqopa inhibits several key cell-signaling pathways, including B-cell receptor signaling, CXCR12 mediated chemotaxis of malignant B cells, and NFκB signaling in lymphoma cell lines.

IMPORTANT SAFETY INFORMATION FOR ALIQOPA® (copanlisib)

Infections: Serious, including fatal, infections occurred in 19% of 317 patients treated with ALIQOPA monotherapy. The most common serious infection was pneumonia. Monitor patients for signs and symptoms of infection and withhold ALIQOPA for Grade 3 and higher infection.

Serious pneumocystis jiroveci pneumonia (PJP) infection occurred in 0.6% of 317 patients treated with ALIQOPA monotherapy. Before initiating treatment with ALIQOPA, consider PJP prophylaxis for populations at risk. Withhold ALIQOPA in patients with suspected PJP infection of any grade. If confirmed, treat infection until resolution, then resume ALIQOPA at previous dose with concomitant PJP prophylaxis.

Hyperglycemia: Grade 3 or 4 hyperglycemia (blood glucose 250 mg/dL or greater) occurred in 41% of 317 patients treated with ALIQOPA monotherapy. Serious hyperglycemic events occurred in 2.8% of patients. Treatment with ALIQOPA may result in infusion-related hyperglycemia. Blood glucose levels typically peaked 5 to 8 hours post-infusion and subsequently declined to baseline levels for a majority of patients; blood glucose levels remained elevated in 17.7% of patients one day after ALIQOPA infusion. Of 155 patients with baseline HbA1c <5.7%, 16 (10%) patients had HbA1c >6.5% at the end of treatment.

Of the twenty patients with diabetes mellitus treated in CHRONOS-1, seven developed Grade 4 hyperglycemia and two discontinued treatment. Patients with diabetes mellitus should only be treated with ALIQOPA following adequate glucose control and should be monitored closely.

Achieve optimal blood glucose control before starting each ALIQOPA infusion. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of hyperglycemia.

Hypertension: Grade 3 hypertension (systolic 160 mmHg or greater or diastolic 100 mmHg or greater) occurred in 26% of 317 patients treated with ALIQOPA monotherapy. Serious hypertensive events occurred in 0.9% of 317 patients. Treatment with ALIQOPA may result in infusion-related hypertension. The mean change of systolic and diastolic BP from baseline to 2 hours post-infusion on Cycle 1 Day 1 was 16.8 mmHg and 7.8 mmHg, respectively. The mean BP started decreasing approximately 2 hours post-infusion; BP remained elevated for 6 to 8 hours after the start of the ALIQOPA infusion. Optimal BP control should be achieved before starting each ALIQOPA infusion. Monitor BP pre- and post-infusion. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of hypertension.

Non-infectious Pneumonitis: Non-infectious pneumonitis occurred in 5% of 317 patients treated with ALIQOPA monotherapy. Withhold ALIQOPA and conduct a diagnostic examination of a patient who is experiencing pulmonary symptoms such as cough, dyspnea, hypoxia, or interstitial infiltrates on radiologic exam. Patients with pneumonitis thought to be caused by ALIQOPA have been managed by withholding ALIQOPA and administration of systemic corticosteroids. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of non-infectious pneumonitis.

Neutropenia: Grade 3 or 4 neutropenia occurred in 24% of 317 patients treated with ALIQOPA monotherapy. Serious neutropenic events occurred in 1.3%. Monitor blood counts at least weekly during treatment with ALIQOPA. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of neutropenia.

Severe Cutaneous Reaction: Grade 3 and 4 cutaneous reactions occurred in 2.8% and 0.6% of 317 patients treated with ALIQOPA monotherapy respectively. Serious cutaneous reaction events were reported in 0.9%. The reported events included dermatitis exfoliative, exfoliative rash, pruritus, and rash (including maculo-papular rash). Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of severe cutaneous reactions.

Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, ALIQOPA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of copanlisib to pregnant rats during organogenesis caused embryo-fetal death and fetal abnormalities in rats at maternal doses as low as 0.75 mg/kg/day (4.5 mg/m2/day body surface area) corresponding to approximately 12% the recommended dose for patients. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment and for at least one month after the last dose.

Adverse Drug Reactions: Serious adverse reactions were reported in 44 (26%) patients. The most frequent serious adverse reactions that occurred were pneumonia (8%), pneumonitis (5%) and hyperglycemia (5%). Adverse reactions resulted in dose reduction in 36 (21%) and discontinuation in 27 (16%) patients. The most frequently observed adverse drug reactions (≥20%) in ALIQOPA-treated patients were: hyperglycemia (54%), leukopenia (36%), diarrhea (36%), decreased general strength and energy (36%), hypertension (35%), neutropenia (32%), nausea (26%), thrombocytopenia (22%), and lower respiratory tract infections (21%).

Drug Interactions: Avoid concomitant use with strong CYP3A inducers. Reduce the ALIQOPA dose to 45 mg when concomitantly administered with strong CYP3A inhibitors.

Lactation: Advise women not to breastfeed. Advise a lactating woman not to breastfeed during treatment with ALIQOPA and for at least 1 month after the last dose.

For important risk and use information about Aliqopa, please see the full Prescribing Information.

About CHRONOS-3

CHRONOS-3 is a Phase III randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Aliqopa in combination with rituximab versus placebo in combination with rituximab in patients with relapsed indolent NHL who have received at least one or more lines of prior rituximab-containing therapy. Histological subtypes included in the trial were follicular lymphoma (FL), small lymphocytic lymphoma (SLL), lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), and marginal zone lymphoma (MZL). Patients who had a progression-free and treatment-free interval of at least 12 months after completion of the last rituximab-containing regimen or patients unwilling/unfit or for who chemotherapy was contraindicated by reason of age, co-morbidities and/or residual toxicity were included (NCT02367040). The study enrolled 458 participants.2

About non-Hodgkin’s Lymphoma

Non-Hodgkin’s Lymphoma (NHL) comprises a highly heterogeneous group of chronic diseases with poor prognosis. NHL is the most common hematologic malignancy and the eleventh most common cancer worldwide, with nearly 510,000 new cases diagnosed in 2018. It accounted for nearly 249,000 deaths worldwide in 2018.6,7

Indolent NHL consists of multiple subtypes, including follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), and lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM). While the disease is typically slowly growing, it can become more aggressive over time. Despite treatment advances, there remains a need for improved treatment options for the relapsed or refractory stage of the disease. After response to initial therapy, response rates and duration of response decline with subsequent lines of therapy, underscoring the need for patients whose disease has already progressed.

About Oncology at Bayer

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

© 2021 Bayer

BAYER, the Bayer Cross and Aliqopa are registered trademarks of Bayer.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

______________________________________________________________________________

References

  1. Matasar, M., Capra, M., Özcan, M., et.al. CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL) CT001. In: Proceedings of the 112th Annual Meeting of the American Association for Cancer Research; 2021 April 10-15. Philadelphia (PA): AACR; 2021. Abstract CT001
  2. ClinicalTrials.gov. Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-3). Available online: https://clinicaltrials.gov/ct2/show/NCT02367040. Last Accessed: March 2021.
  3. Aliqopa (copanlisib) for injection [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; November 2020.
  4. Scott, W.J., Hentemann, M.F., Rowley, R.B., et al. ChemMedChem 2016, 11, 1517-1530. Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: Identification of copanlisib (BAY 806946).
  5. Dreyling, M., Santoro, A., Mollica, L., et al. J. Hematol. 2020, 95, 362-371. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
  6. World Cancer Research Fund. Worldwide cancer data: Global cancer statistics for the most common cancers. Available online: https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data. Last Accessed: March 2021
  7. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018), Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68: 394-424. https://doi.org/10.3322/caac.21492

PP-ALI-US-0689-1 04/21

Contacts

Media Contact:
Rose Talarico, Tel. +1 862.404.5302

E-Mail: rose.talarico@bayer.com

Categories
Business Technology

Vision Solar, a cutting edge renewables company projected to exceed $150M for 2021, hires seasoned CIO, Greg Young, to drive its innovation and digital transformation

BLACKWOOD, N.J. — (BUSINESS WIRE) —#renewables — On March 17th, Vision Solar, which is one of the leaders in Residential Solar Panel Installations, found their “purple unicorn,” and announced Greg Young as their new Chief Information Officer.

Young is a candidate with a profile that possesses the skills and experiences that are rare. Vision Solar with its forward-thinking digital transformation and innovative trajectory, is happy to have Young join their diverse leadership team.

Greg Young has over 20 years of professional experience within the Information Technology Industry. Prior to joining Vision Solar, Greg Young served as Chief Information Officer and Global Vice President for Hardinge Inc. It was here that Young created a proven successful record in integrating scalable technology solutions. His experiences have given him the ability to continuously deliver value by driving organizations to break through operational and performance success.

 

“I’m very excited to join Vision Solar during this time of exponential growth. I look forward to helping the company grow through innovation,” Young stated.

Young’s goal in his new position is to lead Vision Solar’s digital transformation journey by delivering cutting-edge and scalable solutions that drive business results, and provide a competitive edge that differentiates us within Renewables space, in all of our current and future locations, nationwide.


About Vision Solar

Vision Solar is one of the fastest growing solar energy companies in the United States. Their full-service renewable energy company installs solar services for residential homes in Pennsylvania, Arizona, New Jersey, Massachusetts and Florida. Over the past three years, Vision Solar has grossed over $100 million in revenue, with significant increase in projected growth to produce 1000+ high-quality Green Jobs by 2022. To learn more, visit: https://visionsolar.llc

Contacts

John Czelusniak,

jczelusniak@visionsolar.llc

Categories
Technology

BAE Systems starts electronic warfare system production for U.S. Air Force F-15s

NASHUA, N.H.–(BUSINESS WIRE)–BAE Systems has received a $58 million contract from Boeing to start Low Rate Initial Production (LRIP) of the F-15 Eagle Passive Active Warning and Survivability System (EPAWSS) for the U.S. Air Force. The electronic warfare (EW) and countermeasures system provides advanced electromagnetic capabilities that protect pilots and help them maintain air superiority during their toughest missions.


“The start of EPAWSS production marks a critical milestone and is a testament to the dedication and commitment of our industry team,” said Jerry Wohletz, vice president and general manager of Electronic Combat Solutions at BAE Systems. “Our technology is cutting-edge, our factories are world-class, and our people are innovative and mission-focused.”

The all-digital EPAWSS enables pilots to monitor, jam, and deceive threats in contested airspace. The system combines multispectral sensors and countermeasures, industry-leading signal processing, microelectronics, and intelligent algorithms to deliver fully integrated radar warning, situational awareness, geolocation, and self-protection capabilities.

The successful completion of a series of rigorous flight tests, ground tests, and intensive technology demonstrations led to the U.S. Air Force decision to proceed with LRIP. During the program’s Engineering and Manufacturing Development phase, BAE Systems is delivering incremental updates to the EPAWSS flight software with new geolocation and threat identification capabilities. As a result, system performance continues to improve in ground/flight test and in dense signal environments in hardware-in-the-loop (HiTL) tests at the U.S. Air Force’s Integrated Demonstrations and Applications Laboratory.

“I’m proud of the overall team for their incredible effort on this program,” said F-15 EPAWSS program manager Lt Col Dan Carroll. “The LRIP milestone is the culmination of years of hard work by a lot of great people within the government and our Boeing and BAE Systems industry partners. EPAWSS will significantly improve the survivability and utility of the F-15, and will be a great complement to what is already a very capable and lethal aircraft.”

BAE Systems has also demonstrated EPAWSS’ hardware maturity and manufacturing readiness. In anticipation of EPAWSS LRIP and other critical EW production needs, the company has invested more than $100 million in world-class EW laboratories and factories, and has grown its workforce of innovative, mission-focused experts.

Work on the EPAWSS program takes place at BAE Systems facilities in Nashua, New Hampshire; Austin, Texas; and Totowa, New Jersey.

Contacts

Mark Daly, BAE Systems

Mobile: 603-233-7636

mark.g.daly@baesystems.com

www.baesystems.com/US
@BAESystemsInc

Categories
Technology

IMM, Hawthorn River Lending Partner to accelerate digital transformation for community banks

–Digital loan origination solution enables end-to-end electronic processing helping banks close more loans, faster while providing an enhanced customer experience–

RAHWAY, N.J. — (BUSINESS WIRE) — IMM, the only eSignature provider that specializes in digital transaction solutions exclusively for financial institutions, and Hawthorn River, the developer of loan origination software for community banks, today announced the companies have partnered to provide an automated, end-to-end digital loan origination solution, helping community banks close more loans, faster, while enabling a more engaging, modern customer experience.

IMM eSign’s technology will now be integrated into Hawthorn River’s end-to-end, digital loan origination platform, further streamlining and automating the lending process. The integrated solution automatically processes document and facilitates a comprehensive, electronic environment while also providing customers a more dynamic, engaging experience whether in-branch or remote, enabling customers to complete lending transactions (from application to funding) at a time and place that is most convenient to them.

“The synergies between IMM and Hawthorn River were immediately evident, and we are pleased to partner with another technology provider that is focused exclusively on helping community financial institutions accelerate their digital transformation,” said Jon Rigsby, Co-Founder and CEO of Hawthorn River. “We consider IMM an extension of our team and together, our companies continue to collaborate on new and improved solutions that address and solve complex challenges facing community bankers. Our goal is to automate and streamline processes start-to-finish and the integrated solution we developed with IMM not only helps bankers be more productive and get more accomplished, it also provides the digital experience today’s consumer demands.”

Rigsby continued, “IMM also shares our passion for customer service and ensuring we are providing a solution that is tailored to meet the very unique needs of a community financial institution. That is something that is very important to our organization, and unfortunately, isn’t always the top priority for a lot of technology providers. We were immediately impressed with IMM’s commitment to service and recognized that culturally we were both in alignment on this key principle. I am proud of the work we’ve accomplished alongside IMM, and look forward to a long-standing partnership that will continue to benefit community banks for years to come.”

Hawthorn River’s ability to streamline lending by automating operational activities, proactively monitor compliance, and standardize end-to-end loan processes is further enhanced by IMM’s premier eSignature solution, IMM eSign. The integrated solution enables community banks to reduce costs and manual errors, improve security and compliance, while also providing a seamless, streamlined interface for bank employees to create and submit transactions for eSignature. Automating this process and eliminating the chance for human error is critical to creating a comprehensive end-to-end transaction lifecycle.

“Together, IMM and Hawthorn River will continue to exceed borrowers’ desires and expectations,” said Michael Ball, Senior Vice President of markets and strategy at IMM. “Both organizations are driven by their desire to create the best, most valuable products and services for financial institutions. Our partnership with Hawthorn will continue our mission to lead digital transformation for the banking community.”

Powering millions of end-to-end digital transactions each month, IMM eSign seamlessly interfaces with existing business systems to optimize back-office operations and provide a more dynamic and engaging customer experience. The transaction experience is frictionless and easy to use for financial institution employees while maintaining the safety and security for customers to sign documents remotely. IMM is the only eSignature provider that specializes in eSignature and Digital Transaction solutions exclusively for financial institutions.

About IMM

For 24 years, IMM has been the premier provider of eSignature and Digital Transaction solutions designed exclusively for financial institutions. Today, more than 1,300 banks and credit unions use IMM’s eSignature and Digital Transaction Management solutions across the Institution to elevate consumer experiences while streamlining back-office processes in a comprehensive, end-to-end digital processing environment.

For more information, visit www.immonline.com or call 1.800.836.4750. Follow us on LinkedIn, Facebook and Twitter.

About Hawthorn River

Hawthorn River is community banking software designed by community bankers. Our mission is to position community banks to remain competitive and independent in a rapidly consolidating industry. From streamlining the end-to-end lending process to automating specific steps along the way, Hawthorn River helps community banks increase productivity, reduce regulatory risk and elevate the borrower experience. For information, visit https://www.hawthornriver.com.

Contacts

For IMM:

Anna Stanley
anna@williammills.com
251.517.7857


For Hawthorn River:
Jon Rigsby
jrigsby@hawthornriver.com
314.220.5009

Categories
Technology

Hudson Nonstop, powered by Amazon’s just walk out technology, takes flight at Dallas Love Field Airport

Historic Opening Celebrates Company’s Commitment To Delivering Transformative Retail Experiences Tailored Towards Today’s Traveler

EAST RUTHERFORD, N.J. — (BUSINESS WIRE) — Hudson, a travel experience leader with more than 1,000 stores in airports, commuter hubs, landmarks and tourist destinations across North America, today unveiled its first-ever Hudson Nonstop store using Amazon’s Just Walk Out technology at Dallas Love Field Airport (DAL), revolutionizing the in-store shopping experience for travelers with safety, speed, and convenience at the forefront.

Located post-security near Gate 10, the state-of-the-art, 500-square-foot store officially opened its gates to eager Dallas travelers on February 22, bringing the excitement of an innovative, contactless shopping experience and the anticipation of the airport’s first walk-through shopping destination to life.

“The opening of our first Hudson Nonstop store is a significant milestone in delivering on Hudson’s vision for accelerated digital innovation in-store and overall digital transformation across the business,” said Brian Quinn, Executive Vice President and Chief Operating Officer of Hudson. “Hudson Nonstop represents a new way of retailing that emulates an end-to-end digital shopping experience which we believe is the future of retail, even after COVID-19 – we look forward to serving travelers in this exciting new store concept for years to come.”

Hudson’s iconic and distinctive brand style is reflected throughout the DAL store’s design and expansive product offering. The freestanding store design and designated single point of entry and exit provide a sleek aesthetic that welcomes DAL travelers in and allows them to easily navigate the store. Acknowledging the need for social distancing protocols in the COVID-19 environment, the store is designed for one-way traffic and eliminates checkout-line friction to manage crowd control.

With travelers able to seamlessly enter the Hudson Nonstop store with a swipe of their credit card or using “Tap to Pay,” take the products they’re looking for, and then walk out of the store, the store merchandising layout provides visibility to products needed for every travel journey. Whether leisurely browsing or eager to locate a go-to travel necessity, travelers can find a wide selection of Grab & Go food, beverage, and snacks as well as electronics, personal protective equipment (PPE), and health and beauty products throughout the store. The store will also include a selection of Texas-themed merchandise, inspired by the rich history and charm of the Lone Star State.

“There is so much to celebrate as we welcome the first travelers to our Hudson Nonstop store at Dallas Love Field,” said Evan Schut, Senior Vice President, Operations of Hudson. “We thank the DAL management team for their ongoing partnership, and are honored to bring the first Hudson Nonstop store to an airport as collectively dedicated to transforming the travel experience as we are.”

The opening of Hudson Nonstop, which is operated under a joint venture agreement with ACDBE partners Multiplex Inc. and REGALi Inc, complements Hudson’s existing footprint at DAL, which offers over 15 travel convenience and food and beverage stores, including a variety of locally-inspired concepts.

“Hudson Nonstop is a tremendous amenity for our customers,” said Mark Duebner, Director of Dallas Love Field Airport. “We want to keep our concessions program fresh and are always looking for new technology to improve the customer experience.”

While debuting first at DAL, Hudson plans to introduce the Hudson Nonstop concept to additional leading airports across North America in 2021, making contactless shopping opportunities more widely accessible for travelers.

About Hudson

Hudson, a Dufry Company, is a travel experience company turning the world of travel into a world of opportunity by being the Traveler’s Best Friend in more than 1,000 stores in airports, commuter hubs, landmarks, and tourist locations. Our team members care for travelers as friends at our travel convenience, specialty retail, duty free and food and beverage destinations. At the intersection of travel and retail, we partner with landlords and vendors, and take innovative, commercial approaches to deliver exceptional value. To learn more about how we can make your location a travel destination, please visit us at hudsongroup.com.

About Dallas Love Field Airport

Dallas Love Field is leading the evolution of the airport experience. It served nearly 17 million passengers in 2019, the most in its history. DAL is the 2018 and 2019 recipient of the Airport Service Quality Award for North American Airports that serve 15 – 25 million passengers. It is a Global Biorisk Advisory Council STAR Facility.

Contacts

Hudson Media
Cindi Buckwalter

communications@hudsongroup.com

Categories
Technology

NICE Actimize introduces breakthrough AI-powered Watch List screening solution for superior risk management

The advanced watch list filtering solution features real-time screening for parties and payments that leverage AI and biometrics to match and screen for global sanctions

HOBOKEN, N.J. — (BUSINESS WIRE) — Financial services organizations are increasingly challenged to efficiently screen parties and payments against required sanctions lists. With these requirements in mind, NICE Actimize, a NICE (Nasdaq: NICE) business, announces the launch of WL-X, its breakthrough, next-generation Watch List (WL) screening solution leveraging the power of artificial intelligence for superior data management, advanced screening capabilities and frictionless customer onboarding.

NICE Actimize’s WL-X features real-time and on-demand screening for parties and payments that leverages AI and biometrics to match and screen against global sanctions, politically-exposed persons (PEPs), adverse media and other lists. The solution also orchestrates and aggregates list data from premium and public sources with internal lists providing full auditability to ensure accurate screening.

Serving as the foundation for data-driven, advanced screening processes, NICE Actimize’s WL-X solution expedites customer onboarding while reducing friction​.The advanced solution also offers best-in-class detection featuring advanced facial biometrics, intelligent payment parsing in compliance with ISO20022, and the industry’s most advanced culture/name matching technology.

“Sanctions screening is a critical function across AML operations, but it still relies on traditional technology and workflows,” said Neil Katkov, PhD, Head of Risk, at research and advisory firm Celent. “It makes sense to apply the next-generation technologies that are already transforming investigation and other areas of AML to these legacy-burdened processes.”

“NICE Actimize’s innovative screening technology supports financial services organizations looking to boost accuracy and efficiency while complying with global regulations,” said Craig Costigan, CEO, NICE Actimize. “A cost-effective anti-money laundering compliance program includes advanced screening capabilities to reduce regulatory risk, generate high quality matches with lower false positives while speeding operational efficiency. And with NICE Actimize WL-X technology, organizations get all of these benefits.”

Additional features of the next generation NICE Actimize WL-X solution include:

  • Real-time and batch screening capabilities which adhere to regulatory obligations for new and current customers, their counterparties and payments.​
  • Seamless access to aggregated, normalized and verified data from multiple lists sourced from a comprehensive selection of premium and public data sources.​
  • The use of advanced fuzzy matching technologies plus facial biometrics for precise matching capabilities.
  • Machine-learning driven model optimization to adapt and ensure low false positives.
  • Full controls across the AML value chain from onboarding to ongoing monitoring and any ad-hoc checks ​along the way.

NICE Actimize Autonomous Anti-Money Laundering Suite

NICE Actimize’s Autonomous AML modernizes AML programs through a unique combination of AI, machine learning, domain expertise, Intelligent Automation and visual storytelling to better combat money-laundering and terrorist financing. It keeps programs up-to-date with regulatory compliance while creating a single integrated view of the customer. In addition to the new WLF-X solution, the suite includes solutions for Suspicious Activity Monitoring, Customer Due Diligence/KYC, Suspicious Transaction Activity Reporting (STAR), Currency Transaction Reporting (CTR) and X-Sight ActimizeWatch, a secure cloud-based managed analytics service that delivers laser-sharp financial crime detection by actively monitoring analytics performance.

For more information, please visit our web site here.

To join NICE Actimize’s webinar, “Transforming Sanctions Screening: A Discussion with Celent,” please register here.

About NICE Actimize

NICE Actimize is the largest and broadest provider of financial crime, risk and compliance solutions for regional and global financial institutions, as well as government regulators. Consistently ranked as number one in the space, NICE Actimize experts apply innovative technology to protect institutions and safeguard consumers and investors assets by identifying financial crime, preventing fraud and providing regulatory compliance. The company provides real-time, cross-channel fraud prevention, anti-money laundering detection, and trading surveillance solutions that address such concerns as payment fraud, cybercrime, sanctions monitoring, market abuse, customer due diligence and insider trading. Find us at www.niceactimize.com, @NICE_Actimize or Nasdaq: NICE.

About NICE

NICE (Nasdaq: NICE) is the world’s leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. NICE helps organizations of all sizes deliver better customer service, ensure compliance, combat fraud and safeguard citizens. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, are using NICE solutions. https://www.nice.com.

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Costigan, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

Corporate Media Contact
Cindy Morgan-Olson, +1 646 408 5896, ET, cindy.morgan-olson@niceactimize.com

Investors
Marty Cohen, +1 551 256 5354, ET, ir@nice.com
Yisca Erez +972 9 775 3798, CET, ir@nice.com

Categories
Technology

NICE Actimize recognized with 2021 Frost & Sullivan North America Technology Innovation Leadership Award for enterprise fraud management

The analyst report stated that by embracing artificial intelligence, machine learning, and cloud computing, NICE Actimize continuously developed new features and functionalities for enterprise fraud management

HOBOKEN, N.J. — (BUSINESS WIRE) — NICE Actimize, a NICE (Nasdaq: NICE) business, has announced that it is the recipient of the 2021 Frost & Sullivan North America Technology Innovation Leadership Award for enterprise fraud management (EFM). For the Technology Innovation Leadership Award, Frost & Sullivan analysts independently evaluated two key factors — technology leverage and business impact — across ten benchmarking criteria. Frost & Sullivan’s Technology Innovation Award recognizes the company that has introduced the best underlying technology for achieving remarkable product and customer success while driving future business value.

To download a full copy of the “2021 Frost & Sullivan North America Technology Innovation Leadership for Enterprise Fraud Management” report on NICE Actimize and its EFM expertise, please click here.

According to Frost & Sullivan’s analysis of NICE Actimize, “At the foundation of NICE Actimize’s expansive product portfolio lies its Integrated Fraud Management (IFM-X) platform. Launched as a next-generation platform in 2019, IFM-X serves as a fraud hub for NICE Actimize’s clients, combining disparate data streams, adaptive data analytics, artificial intelligence, and machine learning to solve clients’ complex needs with holistic fraud management.

The technology innovation report explained, “The platform includes a variety of packaged solutions specifically designed to enable use cases in authentication management, digital banking fraud, payments fraud, business email compromise, advanced fraud analytics, card and emerging payments fraud, check fraud, and internal threats.”

“NICE Actimize’s leadership and dedication to the industry have led the company to create an extensive portfolio of fraud management products that empower users in an endless number of use cases. By embracing key mega trends such as artificial intelligence (AI), machine learning (ML), and cloud computing, the company continuously developed new features and functionalities that enable its clients to be proactive as they join forces to address the emerging fraud threats,” said Jeffrey Castilla, Best Practices Research Team Leader, Frost & Sullivan. “With its strong overall performance, NICE Actimize earns the 2021 Frost & Sullivan Technology Leadership Award for enterprise fraud management.”

The report also acknowledged NICE Actimize’s continuing commitment to the cloud, observing, “NICE Actimize is positioned to support their clients on their journey with a suite of cloud-based value-added services. The company had already started its journey to the cloud years ago, beginning with ActimizeWatch, its managed analytics service, and subsequently developing into an extensive suite of solutions.”

Additionally, the report cited NICE Actimize’s investment in AI and machine learning targeting its enterprise fraud solutions, explaining, “NICE Actimize continues to evolve it’s AI/ML capabilities with investments in automated and adaptive machine learning, as well leveraging cutting-edge AI/ML techniques like ‘Federated Learning’ to automatically share fraud signals between its risk models, across NICE Actimize’s client base. This allows organizations to be proactively protected from emerging Fraud typologies based on collective intelligence.”

“As a leader in the enterprise fraud management space, NICE Actimize continually innovates with advancements in cloud, artificial intelligence, and machine learning so that financial services organizations more effectively stop emerging fraud threats,” said Craig Costigan, CEO, NICE Actimize. “We thank Frost & Sullivan for identifying NICE Actimize’s differentiators in technology and innovation that support FSOs in their fight against the challenging environment surrounding new and aggressive fraud types.”

The report also noted that in 2020, “NICE Actimize announced a strategic acquisition of a market leader in entity enrichment and resolution. This acquisition became X-Sight DataIQ, which NICE Actimize integrated into its portfolio. X-Sight DataIQ orchestrates the aggregation of entity data across hundreds of public and premium sources to ensure that entity data is always accurate. This intelligence fuels detection accuracy and alert resolution efficiency.”

For additional NICE Actimize resources in enterprise fraud:

For the eBook, “The Future of Fraud Fighting Evolving to Stay Ahead of Threats,” please click here.

For more information on NICE Actimize’s Fraud Management Solutions Suite, please click here.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages more than 50 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from 45 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

About NICE Actimize

NICE Actimize is the largest and broadest provider of financial crime, risk and compliance solutions for regional and global financial institutions, as well as government regulators. Consistently ranked as number one in the space, NICE Actimize experts apply innovative technology to protect institutions and safeguard consumers and investors assets by identifying financial crime, preventing fraud and providing regulatory compliance. The company provides real-time, cross-channel fraud prevention, anti-money laundering detection, and trading surveillance solutions that address such concerns as payment fraud, cybercrime, sanctions monitoring, market abuse, customer due diligence and insider trading. Find us at www.niceactimize.com, @NICE_Actimize or Nasdaq: NICE.

About NICE

NICE (Nasdaq: NICE) is the world’s leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. NICE helps organizations of all sizes deliver better customer service, ensure compliance, combat fraud and safeguard citizens. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, are using NICE solutions. www.nice.com.

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Costigan, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

Corporate Media Contact:

Cindy Morgan-Olson, +1-646-408-5896, NICE Actimize, cindy.morgan-olson@niceactimize.com

Investors
Marty Cohen, +1 551 256 5354,  ir@nice.com, ET

Yisca Erez +972 9 775 3798,  ir@nice.com, CET